Saracatinib has been shown to inhibit purified EGFR variants in a kinase assay; therefore, we attempted to determine whether its effect on EGFR Y1173 phosphorylation observed in NSCLC cell lines may be mediated by Src inhibition. The gene discussed is SRC; the disease is non-small cell lung carcinoma.